

9 December 2024

Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Extraordinary General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Extraordinary General Meeting ("GM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
1. To grant the Directors with authority to subdivide and reclassify the existing ordinary shares.	518,007,554	95.39	25,041,580	4.61	543,049,134	38.74%	1,494,053
2. To grant the Directors with authority to consolidate the New Ordinary Shares.	518,772,622	95.41	24,976,512	4.59	543,749,134	38.79%	794,053
3. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act.	500,896,092	92.24	42,153,042	7.76	543,049,134	38.74%	1,494,053
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
4. To approve the adoption of the New Articles.	514,762,980	94.80	28,213,641	5.20	542,976,621	38.73%	1,566,566
5. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act.	493,949,091	92.78	38,427,061	7.22	532,376,152	37.98%	12,167,035

(1) The Company's issued share capital ("ISC") on 5 December 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,401,815,988 ordinary shares.

(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

Enquiries:

Hemogenyx Pharmaceuticals plc

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

headquarters@hemogenyx.com

peter.redmond@hemogenyx.com

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMEADANEAPLFFA